Panbela Therapeutics (PBLA) Competitors $0.01 +0.00 (+0.91%) As of 10/10/2025 11:27 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. NCNA, SYRS, NKGN, SMFL, VRPX, SCPS, VAXX, TRVN, ARDS, and NAVBShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include NuCana (NCNA), Syros Pharmaceuticals (SYRS), NKGen Biotech (NKGN), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors NuCana Syros Pharmaceuticals NKGen Biotech Smart for Life Virpax Pharmaceuticals Scopus BioPharma Vaxxinity Trevena Aridis Pharmaceuticals Navidea Biopharmaceuticals NuCana (NASDAQ:NCNA) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership. Is NCNA or PBLA more profitable? Panbela Therapeutics' return on equity of 0.00% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets NuCanaN/A -592.28% -208.68% Panbela Therapeutics N/A N/A -302.61% Which has more volatility and risk, NCNA or PBLA? NuCana has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Which has higher valuation & earnings, NCNA or PBLA? NuCana is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuCanaN/AN/A-$24.28M-$646.16-0.01Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00 Do insiders and institutionals believe in NCNA or PBLA? 44.0% of NuCana shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate NCNA or PBLA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Panbela Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to NCNA or PBLA? In the previous week, NuCana had 2 more articles in the media than Panbela Therapeutics. MarketBeat recorded 2 mentions for NuCana and 0 mentions for Panbela Therapeutics. NuCana's average media sentiment score of 0.95 beat Panbela Therapeutics' score of 0.00 indicating that NuCana is being referred to more favorably in the media. Company Overall Sentiment NuCana Positive Panbela Therapeutics Neutral SummaryNuCana beats Panbela Therapeutics on 8 of the 11 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$54K$787.62M$6.05B$10.30BDividend YieldN/A4.84%5.73%4.82%P/E Ratio0.001.2885.1427.10Price / SalesN/A29.85607.17133.24Price / CashN/A17.6425.7730.18Price / Book0.007.5412.646.69Net Income-$25.26M-$7.59M$3.32B$276.55M7 Day PerformanceN/A9.26%-0.07%-0.40%1 Month PerformanceN/A18.72%8.70%6.53%1 Year PerformanceN/A-12.60%78.24%41.04% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.0902 of 5 stars$0.01+0.9%N/A-96.9%$54KN/A0.006NCNANuCana1.3712 of 5 stars$7.02+38.2%N/A-98.6%$150KN/A-0.0130High Trading VolumeSYRSSyros Pharmaceuticals3.7953 of 5 stars$0.01flat$1.00+19,900.0%-99.7%$134K$386K0.00120NKGNNKGen Biotech0.1324 of 5 stars$0.00+150.0%N/A-96.4%$22KN/A0.00N/AGap UpSMFLSmart for LifeN/A$0.00+25.0%N/A-93.7%$18K$11.11M0.00110Gap UpVRPXVirpax Pharmaceuticals0.0509 of 5 stars$0.01flatN/A-99.8%$14KN/A0.007Gap UpSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00-99.0%N/A-97.5%$13KN/A0.0090Gap DownTRVNTrevena1.6174 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030High Trading VolumeNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010 Related Companies and Tools Related Companies NuCana Competitors Syros Pharmaceuticals Competitors NKGen Biotech Competitors Smart for Life Competitors Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Vaxxinity Competitors Trevena Competitors Aridis Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneInvestors are quietly piling into this secret AI stock Elon hates… It's one of those things you just need t...Economic Media | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
